Memantin Orion (Memantine Hydrochloride)

Memantine works by binding to the NMDA‑type glutamate receptor as a non‑competitive antagonist. This blocks excessive calcium entry into neurons caused by over‑activation of glutamate, reducing excitotoxic damage while allowing normal synaptic signaling that supports learning and memory processes.

The dosage of Memantin Orion is individualized. A qualified prescriber determines the appropriate dose and titration schedule based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative treatments when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for Alzheimer’s disease is the acetylcholinesterase inhibitor class (e.g., donepezil). While acetylcholinesterase inhibitors increase cholinergic activity, memantine modulates glutamatergic signaling. Both classes may be used alone or together, offering complementary mechanisms that can improve cognition and daily functioning.

Memantin Orion tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Memantin Orion is taken orally, usually with water. The tablets are swallowed whole and should be taken as directed by the prescribing clinician, often once daily after a gradual titration period to minimize adverse effects.

Serious risks include the potential for seizures, severe allergic reactions such as anaphylaxis, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience rash, difficulty breathing, unexplained fever, or seizure activity.

Memantin Orion is contraindicated in patients with known hypersensitivity to memantine or any excipients in the tablet. Caution is also advised for individuals with uncontrolled severe renal impairment, active seizures, or those taking other NMDA antagonists, unless specifically directed by a physician.